Login to Your Account

Other News To Note

Wednesday, February 27, 2013

• Immune Pharmaceuticals Ltd., of Herzliya-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., said Immune is initiating a Phase II double-blind placebo-controlled study with its lead drug bertilimumab in patients with moderate-to-severe ulcerative colitis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription